Cannabidiol and Tetrahydrocannabinol for HIV-related Neuroinflammation
This study is looking at how cannabidiol (CBD) and tetrahydrocannabinol (THC) affect the gut and brain in people with HIV. Researchers want to understand how these cannabis compounds might impact brain inflammation and the gut microbiome (the community of tiny organisms in your intestines). You might be able to join if you are 21 to 70 years old, have HIV, and have used cannabis at least once in the past five years without serious side effects. Participants will receive either THC capsules or CBD oral solution in a different order over about six weeks. The main goal is to see how these treatments change certain markers from the beginning of the study to weeks 2 and 6. The study's current status is unclear.
- Study design
- This is an interventional study planning to enroll 90 participants. Participants will be randomly assigned to one of two groups and receive treatments in a crossover fashion.
- What's involved
- You would have physical exams, blood tests, and other procedures over a period of about six weeks.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoints are measured at Week 2 and Week 6, suggesting follow-up during this period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Ronald J Ellis, MD, PhD · PRINCIPAL_INVESTIGATOR · UC San Diego
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- PC1Change from baseline to Week 2
A composite marker of inflammation, comprising the first component (PC1, a unitless measure) of the principal component analysis (PCA) of 7 soluble biomarkers in blood (soluble CD163 \[sCD163\], interferon gamma \[IFN-gamma\], interleukin 6 \[IL-6\], C-reactive protein \[CRP\], CC motif chemokine ligand 2 \[CCL2\], neopterin and soluble tumor necrosis factor - type II \[sTNFRII\]), all measured in picograms/milliliter
- PC1Change from Week 4 to Week 6
A composite marker of inflammation, comprising the first component (PC1, a unitless measure) of the principal component analysis (PCA) of 7 soluble biomarkers in blood (soluble CD163 \[sCD163\], interferon gamma \[IFN-gamma\], interleukin 6 \[IL-6\], C-reactive protein \[CRP\], CC motif chemokine ligand 2 \[CCL2\], neopterin and soluble tumor necrosis factor - type II \[sTNFRII\]), measured in picograms/milliliter